However, frequencies of CD86+ cells (7.62 ± 0.93% vs. 5.18 ± 2.11%, p = 0.05) were increased in BD mice after treatment with Abatacept compared to those in non-treated control BD mice (Figure 2(i)). This evidence concerns the gene CD86 and Behcet disease.